Clinical trial · Interventional
Diagnostic Imaging of Bone Metastases in Prostate Cancer Patients
A Prospective Study Comparing the Diagnostic Accuracy of Bone SPECT-CT, Choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and WB-MRI in the Detection of Prostate Cancer Bone Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An improved diagnosis of bone metastases in prostate cancer patients can have a significant impact on treatment strategy and probably survival as well. The primary purpose of the project is to determine the diagnostic accuracy of bone SPECT-CT, choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and Whole-body MRI in the diagnosis of bone metastases in prostate cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Metastatic to Bone | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cholin-PET-CT | Diagnostic Test | — | UNRESOLVED |
| PSMA-PET-CT | Diagnostic Test | — | UNRESOLVED |
| SPECT-CT | Diagnostic Test | — | UNRESOLVED |
| WB-MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- SPECT-CT
- description
- The participants will undergo two project scans: WB-MRI and SPECT-CT
- interventionNames
- Diagnostic Test: WB-MRI
- Diagnostic Test: SPECT-CT
- type
- OTHER
- label
- Cholin-PET-CT
- description
- The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
- interventionNames
- Diagnostic Test: WB-MRI
- Diagnostic Test: Cholin-PET-CT
- type
- OTHER
- label
- PSMA-PET-CT
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: A subject will be eligible for project participation if he meets all of the following criteria: * Is either 1) a newly diagnosed prostate cancer patient in clinical suspicion of bone metastases or 2) a previously diagnosed prostate cancer patient in clinical suspicion of progression in the form of bone metastases. The subject must have been referred to the standard diagnostic imaging (18F-NaF-PET-CT) at our institution for bone metastases. * The prostate cancer diagnosis must be biopsy-proven * The subject is willing and able to comply with the protocol as judged by the investigator Exclusion Criteria: A subject will be excluded from the protocol if he meets one or more of the following criteria: * Has prior malignancy, except for adequately treated basal cell or squamous cell skin cancer * Has pacemaker or implanted devices (eg. cardiac valves, neurostimulator or insulin pump) that cannot be removed, metal clips/metal prostheses from surgery that are not MRI compatible or metallic foreign bodies in the eye (MRI exclusion criteria) * Has any condition that places the subject at an unacceptable risk if he undergoes a diagnostic CT-scan (e.g. history of severe allergic reaction to the contrast agent). * Has severe obesity (\>195 kg is the weight limit for the scanner table) * Has severe claustrophobia
References
Publications (0)
Data not yet available